ReviewThe Urologic clinics of North America2020
Imaging for Metastatic Renal Cell Carcinoma.
Review in The Urologic clinics of North America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05882747 (The Results of Surgery for Renal Cell Carcinoma Metastases in the Pancreas), which is not on this map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Results of Surgery for Renal Cell Carcinoma Metastases in the Pancreas
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Non-systemic treatment of metastatic kidney cancer: systematic review and a case report.Frontiers in oncology · 2025Pooled it
- Pre-operative imaging evaluation of renal cell carcinoma.Revista da Associacao Medica Brasileira (1992) · 2024Guideline
- Diagnostic performance of MRI, SPECT, and PET in detecting renal cell carcinoma: a systematic review and meta-analysis.BMC cancer · 2022Pooled it
- Do patients with metastatic renal cell carcinoma obtain survival benefits from cytoreductive nephrectomy? A population-based study.Journal of cancer research and clinical oncology · 2023Trial
- A slow and silent return: a case of renal cell carcinoma recurring as gastrointestinal bleeding and small bowel obstruction.Journal of surgical case reports · 2026Article
- Multimodality staging of renal cell carcinoma-pearls & pitfalls.Abdominal radiology (New York) · 2026Review
- Patient perspectives on follow-up CT scans after treatment for renal cell carcinoma (RCC): a cross-sectional questionnaire study.Abdominal radiology (New York) · 2026Article
- Imaging response assessment in metastatic renal cell carcinoma: a radiologist's guide to contemporary therapeutic strategies.Abdominal radiology (New York) · 2026Review
- Laparoscopic resection of metachronous metastasis to the contralateral adrenal gland 5 years after radical nephrectomy.International journal of surgery case reports · 2026Article
- Article
- Impact of immune cells on renal cancer risk: a Mendelian randomization analysis with clinical cohort validation.Discover oncology · 2025Article
- Delayed Abscopal Response 3 Years After Robotic Stereotactic Body Radiation Therapy for Renal Cell Carcinoma: A Case Report.Cancer reports (Hoboken, N.J.) · 2025Article
- Molecular mechanisms of renal cell carcinoma metastasis and potential targets for therapy.Frontiers in cell and developmental biology · 2025Review
- Case Report: The integration of chemoradiotherapy and immunotherapy in a patient with advanced-stage renal squamous cell carcinoma and pulmonary metastases.Frontiers in immunology · 2025Article
- TRIM26 inhibits clear cell renal cell carcinoma progression through destabilizing ETK and thus inactivation of AKT/mTOR signaling.Journal of translational medicine · 2024Article
- Characterization ofCancers · 2024Article
- Small Bowel Perforation Due to Renal Carcinoma Metastasis: A Comprehensive Case Study and Literature Review.Diagnostics (Basel, Switzerland) · 2024Article
- Hemoptysis due to a lung metastasis of renal cell carcinoma: A case report.Radiology case reports · 2023Article
- ADAM12 promotes clear cell renal cell carcinoma progression and triggers EMT via EGFR/ERK signaling pathway.Journal of translational medicine · 2023Article
- Proposal for a Two-Tier Re-classification of Stage IV/M1 domain of Renal Cell Carcinoma into M1 ("Oligometastatic") and M2 ("Polymetastatic") subdomains: Analysis of the Registry for Metastatic Renal Cell Carcinoma (REMARCC).Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Patients with renal cell carcinoma may develop metastases after radical nephrectomy, and therefore monitoring with imaging for recurrent or metastatic disease is critical. Imaging varies with specific suspected site of disease. Computed tomography/MRI of the abdomen and pelvis are mainstay modalities. Osseous and central nervous system imaging is reserved for symptomatic patients. Radiologic reporting is evolving to reflect effects of systemic therapy on lesion morphology. Nuclear medicine studies compliment routine imaging as newer agents are evaluated for more accurate tumor staging. Imaging research aims to fill gaps in treatment selection and monitoring of treatment response in metastatic renal cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.